Intensity-modulated radiation therapy for prostate cancer is cost effective and improves therapeutic ratio

References

• Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff. (Millwood) 31(4), 750–759 (2012).
   PubMedGoogle Scholar
• Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost–effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 408–415 (2006).
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975–2007. National Cancer Institution, MD, USA (2010).
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012).
   PubMed Web of Science ®Google Scholar
• Thompson I, Thrasher JB, Aus G et al.; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177(6), 2106–2131 (2007).
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11(11), 1066–1073 (2010).
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26(15), 2497–2504 (2008).
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A et al.; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised Phase III trial. Lancet 373(9660), 301–308 (2009).
   PubMed Web of Science ®Google Scholar
• Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24(13), 1990–1996 (2006).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD et al.; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8(6), 475–487 (2007).
   PubMed Web of Science ®Google Scholar
• Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28(7), 1106–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(1), 67–74 (2008).
   PubMed Web of Science ®Google Scholar
• Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79–84 Gy by a simple four-field coplanar beam arrangement. Int. J. Radiat. Oncol. Biol. Phys. 55(1), 71–77 (2003).
   PubMedGoogle Scholar
• Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high-dose external radiotherapy in relation to rectal dose. Int. J. Radiat. Oncol. Biol. Phys. 18(1), 23–29 (1990).
   PubMed Web of Science ®Google Scholar
• Lawton CA, Won M, Pilepich MV et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int. J. Radiat. Oncol. Biol. Phys. 21(4), 935–939 (1991).
   PubMed Web of Science ®Google Scholar
• De Meerleer GO, Vakaet LA, De Gersem WR, De Wagter C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 47(3), 639–648 (2000).
   PubMedGoogle Scholar
• Ling CC, Burman C, Chui CS et al. Conformal radiation treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int. J. Radiat. Oncol. Biol. Phys. 35(4), 721–730 (1996).
   PubMedGoogle Scholar
• Sheets NC, Goldin GH, Meyer AM et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307(15), 1611–1620 (2012).
   PubMed Web of Science ®Google Scholar
• Michalski JM, Yan Y, Watkins-Bruner D et al. Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of the RTOG 0126 prostate cancer trial: toxicity report. Int. J. Radiat. Oncol. Biol. Phys. 81, S1–S2 (2011).
   PubMedGoogle Scholar
• Zietman A, Goitein M, Tepper JE. Technology evolution: is it survival of the fittest? J. Clin. Oncol. 28(27), 4275–4279 (2010).
   PubMed Web of Science ®Google Scholar
• Zietman A, Ibbott G. A clinical approach to technology assessment: how do we and how should we choose the right treatment? Semin. Radiat. Oncol. 22(1), 11–17 (2012).
   PubMed Web of Science ®Google Scholar
• Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63(3), 765–771 (2005).
   PubMed Web of Science ®Google Scholar
• Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 267–284 (2004).
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Gomellini S et al. A prospective Phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 11–18 (2010).
   PubMed Web of Science ®Google Scholar
• Pollack A, Walker G, Buyyounouski M et al. Five-year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, S1 (2011).
   PubMedGoogle Scholar